 Guidance for evaluation of baseline anemia or suspected treatment-related anemias is provided below. Investigators may consider the following laboratory evaluations in participants with anemia. oHb and CBC with differential (e.g. MCV, RDW, ANC, hematocrit, reticulocytes counts) oPeripheral blood smear for cell morphological assessment oComplete metabolic panel including liver panel-LFTs, bilirubin, LDH, renal function, and serum folate, B12 values and other chemistries oCoagulation factors (PT, PTT, INR) oUrinalysis including culture oIron panel (TIBC, ferritin, Fe)  Discuss further management with Principal Investigator for clinically significant treatment related anemias. 3.3.2 Immune-related adverse events Management of irAEs attributed should include consideration of published guidelines [24] and the investigator’s discretion. oIn addition to above referenced guidelines, the following recommendations should be considered when managing irAEs: Permanent treatment discontinuation is required in case of immune-related Grade 4 rash/inflammatory dermatitis, nephritis, autoimmune hemolytic anemia, hemolytic uremic syndrome, aplastic anemia, immune thrombocytopenia, acquired thrombotic thrombocytopenic purpura inflammatory arthritis, myositis and polymyalgia-like syndrome. For Grade 4 immune-related lymphopenia, permanent treatment discontinuation will be required, if lymphopenia is considered immune- related in nature, no clear alternative explanation exists for the event, and it does not resolve within 14 days. Permanent treatment discontinuation is not required when the AE is manifested by a single laboratory value out of normal range without any clinical correlates. In this case, treatment should be held until the etiology is determined. If the event is not considered immune-related and resolves to Grade ≤ 1, restarting treatment may be considered. For Grade 1 immune-related pneumonitis: continue treatment. If clinically indicated, monitor participants weekly or more frequently as needed with 32 Abbreviated Title: Neoadjuvant IO for HNSCC Version Date: August 31, 2022 history, physical examination and pulse oximetry. If symptoms appear and/or changes in the physical exam are noted, treat as Grade 2.